Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Resignation of Mr Ashok Bothra as Chief Financial Officer of the company w.e.f. August 30, 2025.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.2 pts more than Nifty Microcap 250 and 13.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Tatva Chintan Pharma Chem Limited has informed the stock exchange that Mr. Ashok Bothra has resigned from his role as Chief Financial Officer of the company. His resignation will take effect from August 30, 2025. The company has not yet announced a successor or any interim financial leadership arrangement in this filing. This is a key managerial personnel change at the senior finance leadership level.
A CFO resignation, especially before the financial year-end transition, can create short-term uncertainty around financial reporting and strategic continuity. Shareholders should watch for a timely replacement announcement, as prolonged vacancy at the CFO level may concern investors about governance and financial oversight.